Medical Condition

lymphoma non hodgkin

Total Trials

8

Recruiting Now

8

Trial Phases

Phase 2, Phase 4, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — lymphoma non hodgkin Clinical Trials

How many clinical trials are currently recruiting for lymphoma non hodgkin?

ClinicalMetric currently tracks 8 actively recruiting clinical trials for lymphoma non hodgkin, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 8. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for lymphoma non hodgkin?

lymphoma non hodgkin research spans Phase 1 (3 trials), Phase 2 (5 trials), Phase 4 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a lymphoma non hodgkin clinical trial?

Eligibility criteria for lymphoma non hodgkin trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 4

Top Sponsors

American Society of Clinical Oncology 1 trial

Mayo Clinic 1 trial

Abramson Cancer Center at Penn Medicine 1 trial

Poitiers University Hospital 1 trial

Cancer Research UK 1 trial

Recruiting Clinical Trials

NCT02693535 Phase 2

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Enrollment

4,200 pts

Location

United States, Puert...

Sponsor

American Society of Clinical O...

View Trial →

NCT00626496

Recruiting

Family Study of Lymphoproliferative Disorders

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Abramson Cancer Center at Penn...

View Trial →

NCT04460235 Phase 4

Recruiting

Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma

Poitiers University Hospital

View Trial →

NCT06045910 Phase 1, Phase 2

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

NCT06101381 Phase 1, Phase 2

Recruiting

CD19-directed CAR-T Cell Therapy for R/R Acute Leukemia and Lymphoma

University of Sao Paulo

View Trial →

NCT06343311 Phase 1, Phase 2

Recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Estrella Biopharma, Inc.

View Trial →

NCT07546188

Recruiting

AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.

Grand Hôpital de Charleroi

View Trial →

Related Conditions

multiple myeloma (2) lymphoma b cell (2) high grade b cell lymphoma (2) large b cell lymphoma (2) advanced solid tumors (1) leukemia lymphocytic chronic b cell (1) monoclonal b cell lymphocytosis (1) relapsed diffuse large b cell lymphoma (1) refractory diffuse large b cell lymphoma (1) transformed indolent non hodgkin lymphoma to diffuse large b cell lymphoma (1) vaccine (1) streptococcus pneumoniae (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology